Omeros stock analysis
Want to see OMER full AI Analyst Report?
Omeros (OMER) Stock Price & Analysis
OMER Stock Chart & Stats
- Day’s Range
- $17.08 - $18.04
- 52-Week Range
- $6.59 - $21.24
- Previous Close
- $17.99
- Volume
- N/A
- Average Volume (3M)
- 1.06M
- Market Cap
- $1.30B
- Enterprise Value
- $1.02B
- Total Cash (Recent Filing)
- $131.95M
- Total Debt (Recent Filing)
- $83.77M
- Price to Earnings (P/E)
- 9.2
- Beta
- 1.42
- Next Earnings
- Nov 16, 2026 (Est.)
- EPS Estimate
- 0.02
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Yartemlia Commercial Traction
Yartemlia's strong first full-quarter sales and rapid sequential growth indicate meaningful physician adoption and early market penetration. If prescribing continues expanding, the product can provide a more durable commercial revenue base and improve Omeros's operating leverage over the coming quarters.
U.S. Reimbursement Support
A permanent product-specific J-code and substantial NTAP reimbursement should make Yartemlia easier for providers to bill and support patient access. Consistent commercial payer prior-authorization approvals further strengthen the product's reimbursement infrastructure and adoption potential.
Debt And Dilution Reduction
Repurchasing convertible notes materially lowers outstanding debt, potential share dilution, and future interest expense. These actions improve the capital structure and preserve more economic value for existing shareholders, while reducing financing pressure as Omeros funds commercialization and pipeline development.
Bears Say
Negative Shareholders' Equity
Negative equity leaves Omeros with limited balance-sheet flexibility and makes leverage more difficult to assess cleanly. Although debt has declined, the capital structure remains vulnerable to refinancing needs and adverse operating developments, potentially constraining investment and strategic options.
Persistent Operating Losses And Cash Burn
Large operating and free-cash-flow outflows show that reported earnings have not yet translated into durable cash generation. Combined with persistent negative EBIT across recent annual periods, this raises the likelihood that Omeros will need sustained commercial execution or additional financing to support its plans.
European Regulatory Setback
The negative European regulatory opinion limits Yartemlia's near-term geographic expansion and creates additional uncertainty around approval timing and commercialization investment. Reexamination could change the outcome, but the setback reduces the certainty of a broader international revenue opportunity.
OMER FAQ
What was Omeros’s price range in the past 12 months?
What is Omeros’s market cap?
When is Omeros’s upcoming earnings report date?
How were Omeros’s earnings last quarter?
Is Omeros overvalued?
Does Omeros pay dividends?
What is Omeros’s EPS estimate?
How many shares outstanding does Omeros have?
What happened to Omeros’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Omeros?
What is the TipRanks Smart Score and how is it calculated?
Omeros Stock Smart Score
Company Description
Omeros
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gregory A. Demopulos
- Employees
- 175
- Website
- www.omeros.com
- Address
- The Omeros Building, Seattle, WA, 98119, US
Omeros (OMER) Earnings & Revenues
OMER Earnings Call
Earnings Call SentimentPositive
The call highlights a successful commercial launch for Yartemlia with very strong quarter-over-quarter sales growth (190% gross, 188% net), positive operating cash flow, meaningful balance sheet improvements via share and note repurchases, reimbursement wins (J-code and NTAP), and progress across a diversified pipeline and strategic partnership with Novo Nordisk. Offsetting items include a negative CHMP opinion in Europe, accounting volatility from derivative mark-to-market adjustments and repurchase-related losses, expected near-term increases in operating expenses, limited patient-level visibility, and one-time reimbursement items that temper recurring income visibility. On balance, the operational and commercial positives—especially the rapid U.S. uptake, cash generation, and reduced leverage/dilution—outweigh the challenges, which are largely manageable or noncash/one-time in nature.
View all OMER earnings summariesOMER Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 5 | 9 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 5 | 0 | 7 |
